Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1622
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18634289 | CRYSTALLINE FORMS OF RAS INHIBITORS, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF | Non-Final OA | Revolution Medicines, Inc. |
| 18698748 | COMPOSITIONS AND USES THEREOF FOR TREATMENT OF NEUROLOGICAL DISORDERS | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18524124 | METHODS OF TREAMENT | Non-Final OA | Arena Pharmaceuticals, Inc. |
| 18579830 | PHTHALAZINONE-BASED PARP-1 INHIBITORS | Non-Final OA | Oregon Health & Science University |
| 18331748 | Treatment of Hemophilia with Fitusiran | Non-Final OA | Genzyme Corporation |
| 18688647 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | Non-Final OA | XIZANG HAISCO PHARMACEUTICAL CO., LTD. |
| 18694572 | DEUTERATED POSITIVE NMDA-MODULATING COMPOUNDS AND METHODS OF USE THEREOF | Non-Final OA | SAGE THERAPEUTICS, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy